ClearPoint Neuro (CLPT) Liabilities and Shareholders Equity (2011 - 2026)

ClearPoint Neuro (CLPT) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $93.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 210.66% year-over-year to $93.4 million; the trailing twelve-month figure through Mar 2026 stood at $314.4 million (up 94.04% YoY), and the FY2025 full-year result was $97.7 million, up 149.42% from the prior year.
• Liabilities and Shareholders Equity declined to $93.4 million in Q1 2026, from $97.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $97.7 million in Q4 2025 to a low of $30.1 million in Q1 2025.
• A 5-year average of $55.9 million and a median of $53.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 43.94% in 2025 and surged 210.66% in 2026, its largest moves.
• Tracing CLPT's Liabilities and Shareholders Equity over 5 years: stood at $55.5 million in 2022, then retreated by 23.12% to $42.7 million in 2023, then declined by 8.14% to $39.2 million in 2024, then jumped by 149.42% to $97.7 million in 2025, then slipped by 4.43% to $93.4 million in 2026.
• Business Quant data shows CLPT's Liabilities and Shareholders Equity at $93.4 million in Q1 2026, $97.7 million in Q4 2025, and $60.4 million in Q3 2025.